Haoyunbang Completes a New Round of Financing, Providing Reproductive Health Services

According to VCBeat, Haoyunbang, a company building fertility clinics for infertility, has completed a new round of financing, led by the Zero2IPO Asset Management, with participation from the existing shareholder Pleigran. Proceeds from the latest round will be used to improve medical services and build specialist clinics in China. Previously, Haoyunbang has got investment from Insight Capital, Gene Capital, Green Pine Capital, New Vision Ventures, PWC Capital, and other investors.

The reproductive industry is a field of great concern. There are more than 40 to 50 million infertility patients in China, and with multiple influences such as environment, work pressure, and later fertility age, the prevalence rate continues to rise, bringing growth of the market space.

Since its establishment in 2014, Haokubang has been deeply engaged in the field of reproductive biology. Over the past six years, Haokubang has explored and tried a variety of business models and commercial paths, giving the whole team a deeper understanding of the reproductive industry. Taking advantage of its own online platform, Haokubang insists on taking outpatient service as its core, and gradually formed the closed loop of online platform and online outpatient service. 

Up to now, Haokubang has set up fertility clinics in Beijing, Guangzhou, Jinan, Wuhan and other cities, and has built a reproductive center in Thailand.

The online platform of Haokubang is the largest platform focused on infertility in China, with more than 11 million users and over 10,000 specialists in the reproductive field. In December 2018, the company got the investment from Insight Capital, and used the financing to improve its medical service and professional team instead of clinics expansion, aiming at better medical ability and management.

Zero2IPO Asset Management provides industrial strategy and medium & long-term asset management investment services for listed companies and family enterprises. Currently, it has managed dozens of strategic funds and family funds of listed companies over 20 billion yuan, mainly investing in growth-stage companies in healthcare, consumption upgrading, intelligent manufacturing, culture and entertainment, education and other fields.